Gong Zhen-Yu, Weng Jing-Qing, Lei Jin-Bao, Fang Chun-Fu, Chen En-Fu, Wang Zhen, Chen Zhong-Bing, Wang Wei, He Fan, Liu Bi-Yao, Lin Jun-Fen, Ding Gang-Qiang
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310009, China.
Zhonghua Liu Xing Bing Xue Za Zhi. 2007 Dec;28(12):1190-3.
To evaluate the epidemiological and serological efficacy after 10 years of vaccination against hemorrhagic fever with renal syndrome (HFRS) vaccines in Zhejiang province.
One county was randomly chosen as the research unit with all the healthy people between 16 and 60 years old were equally divided into study and control groups. The study group was vaccinated. Immunofluorescent antibody assay was used to test specific IgG antibody and Mcro-CPE method was used to test the titer of neutralizing antibody.
Two weeks after the full-course immunization, the seroconversion rate became 100% (67/67, with 95% CI as 96.3%-100%) by immunofluorescent antibody test (IgG) and 44.4% (8/18 with 95% CI as 22.0%-69.0%) by neutralization test with GMT titers as 72.1 and 4.6 respectively. Booster immunization was provided one year later. Time span as two weeks prior to, one year, one and half years, two years, three years and five years after booster immunization, the rates of seroconversion on immunofluorescent antibody using IFAT method, were 28.6%, 83.3%, 75.0%, 53.1%, 22.6%, 10.0% and 55.0% respectively, and rates of seroconversion of neutralizing antibody by Mcro-CPE method were 14.8%, 55.6%, 35.0%, 31.3%, 26.0%, 10.0% and 50.0% respectively. Nine years after the reinforcement, the rates of seroconversion of immunofluorescent antibody by IFAT method was only 7.1%. The vaccinated group had no patient seen but the control group appeared 34 patients including 3 deaths. According to the ten-year observation, the vaccine seemed effective with the protection rate in population reached 100%.
HFRS vaccine was effective on epidemiological, social and economical efficacy.
评估浙江省肾综合征出血热（HFRS）疫苗接种10年后的流行病学和血清学效果。
随机选取一个县作为研究单位，将所有16至60岁的健康人群平均分为研究组和对照组。研究组进行疫苗接种。采用免疫荧光抗体法检测特异性IgG抗体，采用微量CPE法检测中和抗体滴度。
全程免疫后两周，免疫荧光抗体检测（IgG）的血清转化率为100%（67/67，95%可信区间为96.3%-100%），中和试验的血清转化率为44.4%（8/18，95%可信区间为22.0%-69.0%），GMT滴度分别为72.1和4.6。一年后进行加强免疫。在加强免疫前两周、一年、一年半、两年、三年和五年的时间点，采用IFAT法检测免疫荧光抗体的血清转化率分别为28.6%、83.3%、75.0%、53.1%、22.6%、10.0%和55.0%，采用微量CPE法检测中和抗体的血清转化率分别为14.8%、55.6%、35.0%、31.3%、26.0%、10.0%和50.0%。加强免疫九年后，采用IFAT法检测免疫荧光抗体的血清转化率仅为7.1%。接种组无病例出现，而对照组出现34例患者，其中3例死亡。根据十年观察，疫苗似乎有效，人群保护率达到100%。
HFRS疫苗在流行病学、社会和经济效益方面均有效。
